Abbott Laboratories (ABT)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-15

$104.89+0.20%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Abbott Laboratories’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.0%

+10% or more+5%0%−5%−10% or less

6.06 → 6.07 EPS · FY ending Dec 31, 2027 · 17 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 18 to 17; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EPS growth to about $5.48 per share in 2026	Adjusted EPS is guided around $5.48 per share for 2026.	Under Pressure	EPS falls below $5.12 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Realize synergies from Exact Sciences acquisition	Abbott's acquisition of Exact Sciences supports growth in oncology diagnostics.	Intact	Failure to realize synergies or integration setbacks reported	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage legal risks including PediaSure lawsuit	The company cleared a major legal risk, reducing uncertainty.	Recovered	Legal rulings cause significant financial or reputational damage	Settled for $670M; no new material adverse impact Abbott settled NEC litigation for $670M, providing legal clarity and reducing risk, while maintaining strong operational growth. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Organic sales growth of 6.5% to 7.5% in 2026	Abbott aims for 6.5% to 7.5% organic sales growth in 2026.	Under Pressure	Organic revenue growth falls below 6.5% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 6 of last 6 quarters. Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% in 2026-Q2 and 2026-Q1, consistent with prior 2025 guidance ranges of 7.5% to 8.0% organic growth. The reported revenue grew from $44.3B in 2025 to $12.6B in 2026-Q2 quarterly sales, reflecting ongoing growth momentum. The trajectory matches management's stated growth target, delivering consistent progress. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$6.07

$6.07 → $6.07 · observed estimates

FY2027 revenue$54.70B

$54.70B → $54.70B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$6.07	$54,698,420,274	16 / 19
2026-07-25	$6.06	$54,629,072,250	24 / 25
2026-07-26	$6.06	$54,629,072,250	24 / 25
2026-07-27	$6.06	$54,680,810,274	16 / 19
2026-07-28	$6.06	$54,629,072,250	24 / 25
2026-07-29	$6.06	$54,648,566,930	25 / 26
2026-07-30	$6.06	$54,648,566,930	25 / 26
2026-07-31	$6.06	$54,648,566,930	25 / 26
2026-08-01	$6.06	$54,648,566,930	25 / 26
2026-08-02	$6.06	$54,648,566,930	25 / 26
2026-08-03	$6.06	$54,648,566,930	25 / 26
2026-08-04	$6.06	$54,648,566,930	25 / 26
2026-08-05	$6.06	$54,648,566,930	25 / 26
2026-08-06	$6.06	$54,648,566,930	25 / 26
2026-08-07	$6.06	$54,648,566,930	25 / 26
2026-08-08	$6.06	$54,698,999,775	17 / 20
2026-08-09	$6.06	$54,648,552,080	25 / 26
2026-08-10	$6.06	$54,648,552,080	25 / 26
2026-08-11	$6.06	$54,698,999,775	17 / 20
2026-08-12	$6.06	$54,648,552,080	25 / 26
2026-08-13	$6.06	$54,648,552,080	25 / 26
2026-08-14	$6.06	$54,698,999,775	17 / 20
2026-08-15	$6.06	$54,698,999,775	17 / 20
2026-08-16	$6.06	$54,698,999,775	17 / 20
2026-08-17	$6.06	$54,698,999,775	17 / 20
2026-08-18	$6.06	$54,698,999,775	17 / 20
2026-08-19	$6.06	$54,698,999,775	17 / 20
2026-08-20	$6.06	$54,698,999,775	17 / 20
2026-08-21	$6.06	$54,697,079,775	17 / 20
2026-08-22	$6.07	$54,696,093,698	17 / 20
2026-08-23	$6.07	$54,696,093,698	17 / 20
2026-08-24	$6.07	$54,696,093,698	17 / 20
2026-08-25	$6.07	$54,696,093,698	17 / 20
2026-08-26	$6.07	$54,696,093,698	17 / 20
2026-08-27	$6.07	$54,696,093,698	17 / 20
2026-08-28	$6.07	$54,696,093,698	17 / 20
2026-08-29	$6.07	$54,696,093,874	17 / 20
2026-08-30	$6.06	$54,696,112,170	17 / 20
2026-08-31	$6.06	$54,696,112,170	17 / 20
2026-09-01	$6.06	$54,696,112,170	17 / 20
2026-09-02	$6.06	$54,696,112,170	17 / 20
2026-09-03	$6.06	$54,696,137,770	17 / 20
2026-09-04	$6.06	$54,696,137,770	17 / 20
2026-09-05	$6.06	$54,696,137,770	17 / 20
2026-09-06	$6.06	$54,696,137,770	17 / 20
2026-09-07	$6.06	$54,696,137,770	17 / 20
2026-09-08	$6.06	$54,696,137,770	17 / 20
2026-09-09	$6.06	$54,696,112,171	17 / 20
2026-09-10	$6.06	$54,696,137,770	17 / 20
2026-09-11	$6.06	$54,696,137,770	17 / 20
2026-09-12	$6.06	$54,696,137,770	17 / 20
2026-09-13	$6.06	$54,696,137,770	17 / 21
2026-09-14	$6.06	$54,696,137,770	18 / 21
2026-09-15	$6.06	$54,696,137,770	18 / 21
2026-09-16	$6.06	$54,696,137,770	18 / 21
2026-09-17	$6.06	$54,696,137,770	18 / 21
2026-09-18	$6.06	$54,696,137,770	18 / 21
2026-09-19	$6.06	$54,696,137,770	18 / 21
2026-09-20	$6.06	$54,696,137,770	18 / 21
2026-09-21	$6.06	$54,696,137,770	18 / 21
2026-09-22	$6.06	$54,696,137,770	18 / 21
2026-09-23	$6.06	$54,696,137,770	18 / 21
2026-09-24	$6.06	$54,696,137,770	18 / 21
2026-09-25	$6.06	$54,696,137,770	18 / 21
2026-09-26	$6.06	$54,696,137,770	18 / 21
2026-09-27	$6.06	$54,696,137,770	18 / 21
2026-09-28	$6.06	$54,696,137,770	18 / 21
2026-09-29	$6.06	$54,696,137,770	18 / 21
2026-09-30	$6.06	$54,696,137,770	18 / 21
2026-10-01	$6.06	$54,696,137,770	18 / 21
2026-10-02	$6.06	$54,698,469,770	18 / 21
2026-10-03	$6.07	$54,699,927,167	18 / 21
2026-10-04	$6.07	$54,699,927,167	18 / 21
2026-10-05	$6.07	$54,699,927,167	18 / 21
2026-10-06	$6.06	$54,695,308,871	18 / 21
2026-10-07	$6.06	$54,695,308,871	17 / 21
2026-10-08	$6.06	$54,695,308,871	17 / 21
2026-10-09	$6.06	$54,695,308,871	17 / 21
2026-10-10	$6.06	$54,700,908,871	17 / 21
2026-10-11	$6.06	$54,700,908,871	17 / 21
2026-10-12	$6.06	$54,700,908,871	17 / 21
2026-10-13	$6.06	$54,700,908,471	17 / 21
2026-10-14	$6.06	$54,700,908,471	17 / 21
2026-10-15	$6.07	$54,700,908,471	17 / 21

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	21	7
2026-06-01	21	7
2026-07-01	21	7
2026-08-01	21	7
2026-09-01	22	6
2026-10-01	24	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 24 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 6 · prior Apr 20

$143.00 → $120.00-16.1%

Redburn PartnersOct 2

$127.00New observation · no comparable prior

$0$78.65$157.30

0 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EPS growth to about $5.48 per share in 2026Published status: Under Pressure
Realize synergies from Exact Sciences acquisitionQualitative condition
Organic sales growth of 6.5% to 7.5% in 2026Published status: Under Pressure

Next proof point

Oct 21, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-36.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Abbott Laboratories outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment is characterized as a durable compounder, focusing on consistent growth in sales and earnings. The current thesis state is stable, supported by recent strong financial performance and reaffirmed guidance.

What's priced into Abbott Laboratories

The market currently prices ABT as cheap compared to its peers, with a slight expectations gap. This suggests that investors may not fully anticipate the potential for growth that management has outlined.

What the fundamentals likely do

Fundamentals are likely to show continued growth, as management is on track to meet its sales and earnings targets. However, there is a moderate risk due to past misses, which could impact investor sentiment.

What Abbott Laboratories hinges on

The thesis hinges on maintaining guidance in upcoming calls and the performance of sector peers. Additionally, broader economic conditions, such as job growth, will play a crucial role in ABT's performance.